Yumanity Therapeutics Investors: Burns McClellan, Inc. Lee Roth (212) 213-0006 ext. 331 Media: Burns McClellan, Inc. Robert Flamm, Ph.D. [email protected] Kineta Jacques Bouchy [email protected] ...

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV ...

--Yumanity Therapeutics, a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative disease, today ...

Yumanity Therapeutics explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law. Investors: Burns McClellan, Inc. Lee Roth [email protected] ...

About YTX-7739 YTX-7739 is Yumanity Therapeutics’ proprietary lead small molecule investigational therapy designed to penetrate the blood-brain barrier and inhibit the activity of a novel target ...

Yumanity Therapeutics is cutting 60% of its workforce by April, while not-so-subtly asking for buyers as the neurodegenerative-focused biotech's early promise begins to fade.

Yumanity was founded in 2016 and went public in 2020 through a reverse merger with another company, cystic fibrosis biotech Proteostasis Therapeutics.

The raise comes after Kineta went public in December through a reverse merger with Boston-based biotech Yumanity Therapeutics Inc. Seattle-based biotech Kineta Inc. has raised about $6 million ...

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) is not the most popular stock in this group but hedge fund interest is still above average. Our overall hedge fund sentiment score for YMTX is 37.9.

Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV ...